APC biallelic loss-of-function mutations are the most prevalent genetic changes in colorectal tumors, but it is unknown whether these mutations phenocopy gain-of-function mutations in the CTNNB1 gene encoding ß-catenin that also activate canonical WNT
Introduction
Personalized medicine has permitted stratification of tumors into subtypes distinguishable by molecular characteristics associated with different prognoses or therapeutic responses.
In colorectal cancer, activating mutations in the KRAS gene, for example, correlate strongly with poor prognosis (1) and guide therapeutic decision-making (2) .
Development of additional markers is needed, however, to define stage-specific characteristics associated with clinical outcomes.
The most prevalent genetic changes in colorectal tumors are biallelic APC mutations; although they have an unclear relationship to outcome (3), they drive dramatic changes in both gene expression and cellular phenotype. We asked whether biallelic loss-offunction APC mutations are equivalent to gain-of-function mutations in the CTNNB1 gene encoding β-catenin, as both mutations activate canonical WNT signaling and occur in a mutually exclusive fashion (4). Mutational data show that CTNNB1 mutations become less prevalent in the tumor spectrum from small adenomas to large adenomas and adenocarcinomas, while APC mutations remain well-represented (5) . This difference in prevalence may be explained by WNT-independent functions of the APC tumor suppressor protein for which loss significantly contributes to colorectal tumor progression (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) , and retention in CTNNB1-mutant tumors may impair progression.
Nuclear APC and chromatin-associated APC interact with β-catenin to inhibit canonical WNT signaling, but may mediate β-catenin-independent transcriptional changes as well.
Previous transcriptional profiling studies of human and murine colon tumors have assumed the equivalence of APC and CTNNB1 mutations in their effects on gene transcription. Our previous work described a transcriptional profiling of adenomas from four murine models of intestinal cancer, focused on the shared characteristics of activated canonical WNT signaling between colon tumors from Apc Min/+ mice and azoxymethane-and dextran sulfate sodium-(AOM/DSS) treated mice now known to harbor Ctnnb1 mutations (16, 17) . The transcriptional evidence of activated canonical WNT signaling in these Apc-and Ctnnb1-mutant tumors stood out in comparison to colon adenomas from mouse models with aberrant Smad/TGFβ1 signaling (16, 17) . Subtle differences between APC and CTNNB1 mutant colorectal tumors were not examined.
This study tests the hypothesis that APC-mutant colon tumors exhibit a set of changes in 
Materials and Methods

Generation of Apc Min/+ and AOM/DSS-treated mouse colon adenomas
Azoxymethane-and dextran sulfate sodium-treated (AOM/DSS) mice were treated as follows: 6-7 week old C57BL/6J mice were given a single intraperitoneal injection of AOM (10 mg/kg body weight). One week later mice were treated with 2% DSS (in drinking water), followed by two weeks on water alone. They received 3 cycles of DSS / water. Mice were sacrificed seventy days after AOM was administered. Apc Min/+ mice on a C57BL/6J background were sacrificed at 110-120 days old. Whole mouse colons were harvested from sacrificed Apc Min/+ and AOM/DSS-treated mice and immediately stored in RNAlater solution (Thermo Fisher Scientific, catalog # AM7020) to protect RNA quality. Single adenomas were excised from the colons of each mouse, and an adjacent section of non-tumor colon tissue was taken as a control. The OSU Institutional Animal Care and Use Committee granted prior approval for all animal studies.
RNA isolation
Tissues were homogenized into 500 μL each of Trizol (Life Technologies catalog # 15596-026) using an OMNI TH tissue homogenizer over a period of 1-2 minutes each.
50 μg glycogen (RNase-free) was mixed into each sample. A standard Trizol isolation protocol was then performed (18) with one modification: Because the mixture appeared 6 cloudy following the addition of isopropanol (due to the precipitation of residual salts from the RNAlater solution), a 50% mixture of nuclease free water and isopropanol was added until the solution became clear. RNA was resuspended in nuclease-free water.
Library preparation and sequencing
Preparation of eight single-read libraries (from three colon adenomas and one adjacent non-adenoma colon tissue from Apc Min/+ mice, and from three colon adenomas and one adjacent non-adenoma colon tissue from AOM/DSS-treated mice) was performed using (24) .
Quantitative PCR validation in an independent set of mouse colon adenomas
RNA-seq results were validated for twelve individual transcripts of interest using independent sets of colon adenomas and non-tumor colon tissues from each mouse model. RNA was isolated from three colon adenomas and three adjacent non-tumor colon tissue samples from three different Apc Min/+ C57BL/6J mice, and from three colon adenomas and three adjacent non-tumor colon tissues samples from a single AOM/DSStreated C57BL/6J mouse. cDNA was reverse transcribed from 1 μg of total RNA as previously described, and 100% conversion to cDNA was assumed for calculation purposes. qPCR was performed in 20-μL reactions with final concentrations of 300nM of each primer and 10 ng of total cDNA, using Power SYBR Green PCR Master Mix (Applied Biosystems). Primer sets were designed to span exon junctions (whenever possible) and were confirmed to amplify cDNA with a single melting temperature.
Analysis of gene expression as a potential marker for disease-free survival
Clinical data measuring time to recurrence or death was available for the 357 tumors from the "TCGA Provisional" dataset, provided in the "Disease-Free (Months)" category, or in the "Overall Survival (Months)" category when the former was not available.
Tumors were sorted into two groups for each transcript of interest, based on expression levels higher or lower than the median. Kaplan-Meier curves were constructed comparing disease-free survival in the high-expression and low-expression subgroups, and statistical significance was evaluated using the Cox-Mantel Log-Rank test (FDR < 0.05). A similar validation analysis was performed using 242 tumors from the "TCGA" dataset. 
Analysis of gene expression as a potential marker for APC mutational status
Genes increased in expression in
Results
Transcriptional profiling of colon adenomas and adjacent colon tissues
This study tests the hypothesis that chromatin-associated APC protein regulates the transcription not only of canonical WNT target genes but also that of WNT/β-cateninindependent target genes. Initial experiments were designed to identify transcripts altered in Apc-mutant colon adenomas but not in Ctnnb1-mutant colon adenomas in which β-catenin is rendered resistant to degradation with chromatin-associated Apc functions Interestingly, upstream regulation by the interleukin-10 receptor (IL10RA) was predicted to decrease significantly, indicating that the synthesis of proinflammatory cytokines (blocked by IL10RA) may be high in both adenoma types, likely due to the presence of infiltrating immune cells (27) .
Adenomas from Apc Min/+ mice exhibit unique transcriptional changes consistent with both transcriptional and non-transcriptional tumor suppressor functions of the Apc protein, associating with pathways such as cell proliferation, formation of cellular protrusions and apoptosis (Fig. 3A) . IPA predicts increases in cell proliferation and viability and suggests a corresponding decrease in apoptosis as well. Apc is known to control proliferation by antagonizing the transcription of canonical WNT target genes such as those encoding c-Myc and Cyclin D1 (28, 29) . APC also regulates the formation of membrane protrusions (30, 31) , interacts with microtubules and facilitate their attachment to kinetochores (9-11) and links the microtubule network to the actin cytoskeleton (32).
Apc promotes apoptosis both by negatively regulating the expression of pro-survival canonical WNT signaling targets such as survivin (33) and by directly localizing to the mitochondria and promoting caspase activity (15, 34, 35) . These results motivated our choice to focus subsequent experiments on transcriptional changes unique to adenomas from Apc Min/+ mice. Three panels of representative transcripts were assembled from the RNA-seq data to summarize differences in gene expression between adenomas from Apc Min/+ and AOM/DSS-treated mice in the pathways regulating cell proliferation (Fig. 4A) , the formation of cell protrusions ( Transcripts encoding proteins linked to apoptotic pathways (Fig. 4B) (40)) exert a pro-apoptotic effect.
Transcripts linked to chromosome segregation and cytoskeletal organization (Fig. 4C) encode kinesins and other microtubule-associated proteins (Kif2a, Map6 ( 
Filtering transcripts differentially expressed in adenomas from Apc Min/+ mice using datasets from mouse models of canonical Wnt signaling inactivation
The lists of transcripts unique to each adenoma type were narrowed down by the removal of those differentially expressed by at least 1.5-fold in the opposite adenoma type relative to non-adenoma tissue. Transcripts unique to adenomas from Apc Min/+ mice were reduced in this manner from 231 to 148, while transcripts unique to adenomas from AOM/DSS-treated mice were narrowed from 139 to 92 (Fig. 1) . We also sought to facilitate the removal of canonical WNT target genes from transcripts unique to adenomas from Apc Min/+ mice. This was performed using two publicly available datasets 
Filtering transcripts differentially expressed in adenomas from Apc Min/+ mice using APC
ChIP-seq data
Human orthologs were identified for 120 of the 133 genes differentially expressed in colon adenomas from Apc Min/+ mice and for 81 of the 92 genes differentially expressed in colon adenomas from AOM/DSS-treated mice. These were compared with an APC ChIP-seq dataset generated from the HCT-116 human colon cancer cell line that is wildtype for APC but mutated at CTNNB1. APC-associated genomic regions were identified by immunoprecipitation from the chromatin fraction of these cells, followed by massively parallel sequencing (ChIP-seq), as described previously (22 
In silico analysis of gene expression data from human colorectal tumors
The relationship between gene expression and clinical variables in human colorectal tumors was examined using The Cancer Genome Atlas (TCGA) RNA-seq data from (Fig. S3) .
Analysis of gene expression as a potential marker for disease-free survival
Tumors were sorted into two groups for each transcript of interest, based on expression levels higher or lower than the median. Kaplan-Meier curves ( (Fig. S5) . We hypothesize that these findings reflect the shortcomings of the validation dataset rather than of the markers, as median follow-up times for patients in the "TCGA"
(validation) and "TCGA Provisional" (discovery) datasets are 0.99 months and 10.07 months, respectively. Accordingly, MAP6, PXDC1 and MSRB3 merit further study as potential markers as more complete patient outcome data become available. Another large dataset using a microarray platform was available through NCBI's Gene Expression Omnibus (accession number GSE39582, (49)) and similarly showed a relationship between disease-free survival and expression of MACC1, MAP6 and MSRB3 that matched the expected trends but did not meet the requirement for an FDR < 0.05 (data not shown).
Analysis of gene expression as a potential marker for APC mutational status
The expression of some known canonical WNT target genes correlates well with APC status while others do not, suggesting that malignant colorectal tumors may be more complex than colorectal adenomas. Nevertheless, genes increased in expression in Apc Min/+ adenomas relative to non-adenomatous tissue were hypothesized to exhibit increased expression in APC-mutant tumors relative to their counterparts with wild-type APC. Gene expression of SERPINE2 was examined in 242 tumors from the "TCGA" dataset, of which 203 had been sequenced at the APC locus (Fig. 6 ). Tumors were divided into two subgroups of 55 "APC wild-type" tumors (including those with missense mutations) and 148 'APC mutant" tumors (including those with frameshift mutations or other premature stop codons detected in either or both alleles of APC). SERPINE2
expression was predicted to increase in APC mutant tumors relative to the wild-type counterparts. The CCND1 and MYC genes were similarly evaluated as controls to illustrate the larger trend that expression of some canonical WNT target genes such as MYC correlates with APC status in malignant tumors while other targets such as CCND1
do not exhibit this pattern. The MACC1 gene was evaluated as a negative control unrelated to APC status. Statistical significance was evaluated using one-tailed Student's t-test (FDR < 0.05). SERPINE2 expression is in fact significantly higher in the APCmutant subset than in the APC-wild-type group (FDR < 0.0213), albeit to a lesser degree in comparison to MYC expression (Fig. 6 ).
Predictive value of SERPINE2 expression as a potential marker for stage
Positive and negative predictive values ( (Fig. 3A) .
These functional pathways are relevant to tumorigenesis and linked to known phenotypes of APC loss (8, 11, 15, 39) . We applied several screening steps ( (Fig. 5 ). This finding is consistent with known functions of its protein product. SERPINE2 encodes the Serpin peptidase inhibitor, Clade E (also known as gliaderived nexin or nexin, plasminogen activator inhibitor type 1, member 2), a secreted protein that can inhibit the serine proteases thrombin, urokinase, plasmin and trypsin (52) . While gene ontology identified it as an anti-apoptotic molecule (Fig. 4 ), SERPINE2
interacts with extracellular matrix components such as heparin and heparan sulfate (53);
its inhibition of thrombin promotes neurite extension (52) . In the context of colorectal cancer cell lines, it exerts a pro-tumorigenic effect by inhibiting a serine protease known as prostasin (54) . Its expression is required for anchorage-independent growth, cell migration and xenograft tumor formation in both APC wild-type and APC mutant colorectal cancer cell models (55) . Therefore, despite the strong correlation between SERPINE2 levels and APC status in colorectal cancer, it is likely that overexpression can be triggered independently of APC loss, with similar consequences for tumor progression. SERPINE2 also promotes extracellular matrix production and invasion in a pancreatic cancer model (56) . These functions are consistent with its increased expression in higher stage tumors (Fig. 5 ) and with the hypothesis that transcripts aberrantly expressed specifically in APC-mutant tumors contribute to tumor progression.
SERPINE2 expression correlates significantly with APC status (Fig. 6) but not with disease-free survival (Fig. S4) . Rather, its future utility may hinge upon its ability to predict tumor stage (Fig. S6) . The ability of SERPINE2 expression levels to predict colorectal staging is somewhat less than that of the established marker MACC1, and (Fig. S8) . This is typical of some wellcharacterized APC-regulated genes such as the canonical WNT target MYC (Fig. S8) , and may reflect the complexity of cell line models with a baseline of activated canonical WNT signaling as a context in which to study APC-dependent effects. This may be explained in part by the tendency of APC modulation to trigger negative feedback through the canonical pathway.
While SERPINE2 expression was the sole transcriptional marker identified in adenomas from Apc Min/+ mice that significantly correlated with clinical variables in multiple human tumor datasets, MAP6, MSRB3 and PXDC1 were identified as potential markers of shorter disease-free survival when expressed at high levels (Fig. S4) . Like SERPINE2, MAP6 encodes a protein product (microtubule-associated protein 6) best known in neuronal cell types, where it binds and stabilizes microtubules (41) and functions in the formation of neuronal cell protrusions (57) . MSRB3 encodes methionine sulfoxide reductase B3, an enzyme linked to apoptosis that localizes in part to the mitochondria and exerts anti-apoptotic functions (38) . PXDC1 encodes PX domain containing 1, a protein of unknown function that includes a predicted phosphatidylinositol binding domain, possibly enabling it to associate with the plasma membrane and implicating it in membrane trafficking. All three targets exhibit expression patterns significantly associated with stage ( Fig. 5 ) and disease-free survival (Fig. S4 ) in the larger "TCGA Provisional" dataset, but fall short of the threshold for significance in the smaller "TCGA" dataset (Fig. S5 ). These genes of interest merit further validation as larger or more complete datasets become available.
These correlations to clinical outcomes in malignant tumors are not sufficient to prove that APC deficiency drives transcriptional changes in adenomas that persist continuously into late stage adenocarcinomas. Changes in the transcription of targets such as SERPINE2 during colorectal cancer progression cannot be attributed solely to APC mutational status, but rather indicate that APC-driven transcriptional changes in adenomas may exert additive effects on apoptosis and cell motility that contribute to tumor progression and are absent from CTNNB1 mutant tumors with wild-type APC.
Future studies in human colon cancer cell lines will be required to characterize the mechanism(s) by which APC regulates each novel transcript involved in apoptosis or cytoskeletal organization, and to determine the extent to which APC effects on their transcription are due to WNT-independent or WNT-dependent mechanisms.
Collectively, the identification of these markers may supplement current studies of tumor staging to predict microscopic metastatic dissemination with greater accuracy. Twenty target genes of the canonical WNT signaling pathway were examined in RNAseq data generated from adenomas and non-adenoma tissues from AOM/DSS-treated (red) and Apc Min/+ (blue) mice. Eighteen transcripts changed in expression by at least two-fold in both adenoma types. Birc5 and Ephb3 increased by more than 2-fold in adenomas from Apc Min/+ mice but by less than 1.5-fold in adenomas from AOM/DSStreated mice. Expression is shown as a fold-change relative to their respective adjacent colon tissue controls. Error bars depict standard deviation among the three adenoma replicates. transcripts differentially expressed in adenomas from AOM/DSS-treated mice (B), and 830 transcripts differentially expressed in both adenoma types relative to matched adjacent colon tissue (C) were subjected to gene ontology analysis using Ingenuity Pathway Analysis software. Fold-changes in expression were submitted and functional categories predicted to be increased (red) or decreased (blue) are indicated. Statistically significant predictions of increases or decreases were defined by enrichment scores at least 2 standard deviations from the mean (Z-score of great than 2 or less than -2). 
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Representative transcripts of genes that regulate cell proliferation (A), apoptosis (B) and formation of cell protrusions (C) were selected for adenomas from Apc Min/+ mice. Each panel contains RNA-seq data from 3 colon adenomas and 1 adjacent colon tissue of each type. Expression is shown in each type of mouse adenoma (in red and blue) as a foldchange relative to their respective non-adenoma colon tissue controls. Error bars depict standard deviation between the three adenomas. The Student's t-test was performed to assess statistically significant differences in fold-change between adenomas from Apc Min/+ and AOM/DSS-treated mice (FDR < 0.05). The Myc and Ccnd1 transcripts (indicated by green arrows) were included as negative controls similarly altered in both adenoma types. Genes increased in expression in adenomas from Apc Min/+ mice relative to non-adenoma tissue were hypothesized to increase in expression in APC mutant human tumors. SERPINE2 expression was examined in 242 tumors from the "TCGA" dataset, of which 203 had been sequenced at the APC locus. Tumors were divided into two subgroups of 55 "APC wild-type tumors" (including those with missense mutations) and 148 'APC mutant tumors" (including those with frameshift mutations or other premature stop codons detected in either or both alleles of APC). Statistical significance was evaluated using one-tailed Student's t-test (FDR < 0.05). The CCND1 and MYC genes were evaluated as a pair of negative and positive controls to illustrate the point that only certain canonical WNT targets correlate in expression with APC status. The MACC1 gene was similarly evaluated as a negative control.
